Ustianowski, Andrew

Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report

Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · New England Journal of Medicine

COVID-19 Clinical Research StudiesRespiratory Support and Mechanisms

Cited by 11,475

Diagnostics for the developing world

Mabey, D., Peeling, R. W., Ustianowski, A., & Perkins, M. D. (2004) · Nature Reviews Microbiology

Biosensors and Analytical DetectionBacterial Identification and Susceptibility Testing

Cited by 1,054

Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial

Writing Committee for the REMAP-CAP Investigators, Abdelhady, H., Abdelrazik, M., Abdi, Z., Abdo, D., Abdulle, A., Abel, L., Abouzeenni, S., Abrahamson, G., Abusamra, Y., et al. (2021) · JAMA

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 212

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Munro, A. P. S., Feng, S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., et al. (2022) · The Lancet Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 175

Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials

The LOVIT-COVID Investigators, O. B. O. T. C. C. C. T. G., Florescu, S., Stanciu, D., Zaharia, M., Kosa, A., Codreanu, D., Fareed, K., Kidwai, A., Kaye, C., Coutts, A., et al. (2023) · JAMA

Vitamin C and Antioxidants ResearchCOVID-19 Clinical Research Studies

Cited by 55

GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults

Palmer, C. D., Scallan, C. D., Kraemer Tardif, L. D., Kachura, M. A., Rappaport, A. R., Koralek, D. O., Uriel, A., Gitlin, L., Klein, J., Davis, M. J., et al. (2023) · Nature Communications

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 42

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial

Moyle, G., Assoumou, L., de Castro, N., Post, F. A., Curran, A., Rusconi, S., De Wit, S., Stephan, C., Raffi, F., Johnson, M., et al. (2024) · The Lancet HIV

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 6